While most of the mTOR inhibitors have not achieved their primary endpoints in cancer clinical trials, they offer promising drug repurposing opportunities in the treatment of non-cancer diseases, as they have already undergone safety and tolerability evaluations and are ready for clinical use. The gene discussed is MTOR; the disease is cancer.